Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status
Authors:
- 19 November 2023
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (2) , 166962
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate AntigensMolecular Cancer Therapeutics, 2012
- Effect of γ34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain TumorsJournal of Virology, 2012
- Systemic Delivery of Oncolytic Viruses: Hopes and HurdlesAdvances in Virology, 2012
- Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cellsNature Immunology, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humansJournal of Experimental Medicine, 2009
- History of Oncolytic Viruses: Genesis to Genetic EngineeringMolecular Therapy, 2007
- THE B7 FAMILY REVISITEDAnnual Review of Immunology, 2005
- HODGKIN'S DISEASE: REMISSIONS AFTER MEASLESThe Lancet, 1971